文献速递放疗物理与技术姑息放疗与转移瘤

手术联合隔日短程放疗治疗瘢痕疙瘩的疗效

Treatment outcomes of surgery followed by short-course every other day radiotherapy in keloid.
PubMed 文献 · Radiat Oncol · 2024-07-17

该回顾性分析纳入2010年1月至2017年12月在本院接受治疗的498例瘢痕疙瘩患者,术后24小时内开始电子束放疗16 Gy分4次隔日照射。中位随访68.1个月后130例(26.5%)复发,1年、3年、5年局部控制率分别为89.5%、82.5%、81%;疼痛和/或瘙痒是复发的独立预后因素(p<0.0001)。作者认为该方案可获得满意的局部控制率,并建议开展前瞻性随机对照试验进一步验证。

要点

  • 术后24小时内开始电子束放疗16 Gy分4次隔日照射,5年局部控制率为81%。
  • 疼痛和/或瘙痒是瘢痕疙瘩复发的独立预后因素(p<0.0001)。
  • 有疼痛或瘙痒症状者1年、3年、5年局部控制率分别为45%、12.5%、8.8%,无此症状者分别为98.8%、95.9%、95%。

核心结论

  • 作者认为手术联合隔日短程放疗可使瘢痕疙瘩获得满意的局部控制率,疼痛和/或瘙痒是复发的独立预后因素,并建议开展前瞻性随机对照试验进一步验证这些结果。

研究设计与样本

  • 回顾性分析2010年1月至2017年12月在本院接受治疗的498例瘢痕疙瘩患者,所有患者术后24小时内开始电子束放疗16 Gy分4次隔日照射,主要终点为局部控制率。

主要发现

  • 中位随访68.1个月(42.6-129.9个月)后,130例(26.5%)瘢痕疙瘩复发。
  • 全部患者1年、3年、5年局部控制率分别为89.5%、82.5%、81%。
  • 复发率最高的部位为胸部(50.8%),其次为耻骨上(47.8%)、头颈部(38.8%)、四肢(33.3%)和耳部(14%)。
  • 多因素与单因素分析均显示疼痛和/或瘙痒是瘢痕疙瘩复发的独立预后因素(p<0.0001)。
  • 有疼痛或瘙痒症状者1年、3年、5年局部控制率分别为45%、12.5%、8.8%,无此症状者分别为98.8%、95.9%、95%(HR 37.829,95%CI 24.385-58.686,p<0.001)。

关键数值与推荐

  • 放疗剂量为16 Gy分4次隔日照射,术后24小时内开始。
  • 耳部瘢痕疙瘩亚组中有瘙痒者1年、3年、5年局部控制率分别为60.0%、26.7%、26.7%,无疼痛或瘙痒者分别为97.9%、94.7%、94.3%(HR 30.209,95%CI 14.793-61.69,p<0.001)。
  • 其他部位也发现相同结果(p<0.001)。

临床怎么用

  • 作者认为手术联合隔日短程放疗可使瘢痕疙瘩获得满意的局部控制率。
  • 作者建议开展前瞻性随机对照试验进一步验证这些结果。

局限性

  • 本研究为回顾性分析。
  • 作者在结论中建议开展前瞻性随机对照试验以进一步验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative radiotherapy can significantly reduce keloid recurrence. However, consensus on the optimal radiotherapy dose and treatment schedule remains elusive. This study aims to evaluate the effectiveness of surgery followed by a short-course of radiotherapy administered every other day for keloid treatment. MATERIALS/METHODS: We conducted a retrospective analysis of 498 patients with keloids treated at our institution between January 2010 and December 2017. All patients underwent electron beam irradiation at a dose of 16 Gy, delivered in four fractions every other day, starting within 24 h post-surgery. The primary endpoint of the study was the local control rate. RESULTS: A total of 130 (26.5%) keloids recurred after a median follow-up of 68.1months (42.6-129.9 months). The local control rates at 1 year, 3 years and 5 years for all patients were 89.5%, 82.5% and 81%, respectively. The highest recurrence rate was observed in keloids located in the chest region (50.8%), followed by the suprapubic (47.8%), head and neck (38.8%), limbs (33.3%) and ear (14%). Both multivariate and univariate analyses identified the presence of pain and or pruritus as an independently prognostic factor for keloid recurrence (p<0.0001). The local control rates at 1-year, 3-years and 5-years for patients with or without symptom of pain or pruritus were 45% vs. 98.8%, 12.5% vs. 95.9%, and 8.8% vs. 95%, respectively (HR:37.829, 95%CI: 24.385-58.686, p<0.001). In the ear keloid subgroup, the 1-year, 3-year and 5-year local control rates for patients with pruritus were significantly lower than those without pain or pruritus (60.0% vs. 97.9%, 26.7% vs. 94.7%, 26.7% vs. 94.3%, HR:30.209, 95% CI:14.793-61.69, p<0.001). The same results were found in other location(p<0.001). During treatment and follow-up, two patients experienced infections, and one patient developed a cutaneous fibroblastoma. CONCLUSION: This study suggests that a combination of surgery followed by short-course, every-other-day radiotherapy can yield satisfactory local control rates for keloids. Pain and or pruritus symptom was an independently prognostic factors for recurrence of keloid. To further validate these results, a prospective randomized controlled trial is recommended.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou W, Li B, Yin Y, et al. Treatment outcomes of surgery followed by short-course every other day radiotherapy in keloid. Radiat Oncol. 2024. PMID: 39020400. doi:10.1186/s13014-024-02488-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。